Shire punts late-stage biosim­i­lars of Hu­mi­ra and En­brel back to Mo­men­ta, Co­herus

Just days af­ter Am­gen won an FDA ap­proval for the first biosim­i­lar of Ab­b­Vie’s Hu­mi­ra, Shire $SH­PG has de­cid­ed to throw away its part­ner­ship rights in a ri­val pro­gram now in Phase III. Shire si­mul­ta­ne­ous­ly cut loose of a sep­a­rate deal with Co­herus $CHRS on de­vel­op­ing an En­brel biosim­i­lar, which was al­so in­her­it­ed in its Bax­al­ta ac­qui­si­tion.

Cam­bridge, MA-based Mo­men­ta Phar­ma­ceu­ti­cals says Shire is hand­ing back rights to M923, one of sev­er­al copy­cats of the megablock­buster au­toim­mune drug. But Shire re­mains on the hook for its share of the de­vel­op­ment costs for an­oth­er year, which may well take this drug right up to an FDA ap­pli­ca­tion. Co­herus, mean­while, says that it has suc­cess­ful­ly nav­i­gat­ed a pair of Phase III stud­ies for CHS-0214 and will now rec­og­nize $162.6 mil­lion as col­lab­o­ra­tion and li­cense rev­enues in 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.